In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma

Bone

Volumn 53, Issue 2, 2013, Pages 487-496

  Pozzi, Samantha ^a,b,e   Fulciniti, Mariateresa ^b,e   Yan, Hua ^a,e   Vallet, Sonia ^a,b,e   Eda, Homare ^a,e   Patel, Kishan ^a,e   Santo, Loredana ^a,b,e   Cirstea, Diana ^a,b,e   Hideshima, Teru ^b,e   Schirtzinge, Linda ^c   Kuhstoss, Stuart ^c   Anderson, Kenneth C ^b,e   Munshi, Nikhil ^b,e   Scadden, David ^a,e   Kronenberg, Henry M ^d   Raje, Noopur ^a,b,e  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Dkk1; Multiple myeloma; Osteoblast; Osteoclast; Wnt

Indexed keywords

ANTINEOPLASTIC AGENT; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CROSS REACTION; FETUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CELLS, CULTURED; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; X-RAY MICROTOMOGRAPHY;

EID: 84873487461     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.01.012     Document Type: Article

References (33)

1. Raje N., Roodman G.D. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011, 17:1278-1286.
2. Roodman G.D. Pathogenesis of myeloma bone disease. J Cell Biochem 2010, 109(2):283-291.
3. Giuliani N., Mangoni M., Rizzoli V. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp Hematol 2009, 37:879-886.
4. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
5. Takahashi-Yanaga F., Kahn M. Targeting, Wnt signaling: can we safely eradicate cancer stem cells?. Clin Cancer Res 2010, 16:3153-3162.
6. Glinka A., Wu W., Delius H., Monaghan A.P., Blumenstock C., Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998, 391:357-362.
7. Marvin M.J., Di Rocco G., Gardiner A., Bush S.M., Lassar A.B. Inhibition of Wnt activity induces heart formation from posterior mesoderm. Genes Dev 2001, 15:316-327.
8. Fleming H.E., Janzen V., Lo Celso C., Guo J., Leahy K.M., Kronenberg H.M., et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2008, 2:274-283.
9. Sato N., Yamabuki T., Takano A., Koinuma J., Aragaki M., Masuda K., et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010, 70:5326-5336.
10. Hoshida Y., Nijman S.M., Kobayashi M., Chan J.A., Brunet J.P., Chiang D.Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385-7392.
11. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
12. Kaiser M., Mieth M., Liebisch P., Oberlander R., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008, 80:490-494.
13. Politou M.C., Heath D.J., Rahemtulla A., Szydlo R., Anagnostopoulos A., Dimopoulos M.A., et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006, 119:1728-1731.
14. Heider U., Kaiser M., Mieth M., Lamottke B., Rademacher J., Jakob C., et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009, (82):31-38.
15. Lemaire O., Attal M., Bourin P., Laroche M. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma. Eur J Haematol 2010, 84:276-277.
16. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., Jr Shaughnessy J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109:2106-2111.
17. Heath D.J., Chantry A.D., Buckle C.H., Coulton L., Jr Shaughnessy J.D., Evans H.R., et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2009, 24:425-436.
18. Fulciniti M., Tassone P., Hideshima T., Vallet S., Nanjappa P., Ettenberg S.A., et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009, 114:371-379.
19. Qiang Y.W., Chen Y., Brown N., Hu B., Epstein J., Barlogie B., et al. Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myeloma. Br J Haematol 2010, 148:726-738.
20. Agholme F., Isaksson H., Kuhstoss S., Aspenberg P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 2011, 48:988-996.
21. Fulciniti M., Hideshima T., Vermot-Desroches C., Pozzi S., Nanjappa P., Shen Z., et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009, 15:7144-7152.
22. Pozzi S., Vallet S., Mukherjee S., Cirstea D., Vaghela N., Santo L., et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009, 15:5829-5839.
23. Vallet S., Raje N., Ishitsuka K., Hideshima T., Podar K., Chhetri S., et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007, 110:3744-3752.
24. Raje N., Kumar S., Hideshima T., Roccaro A., Ishitsuka K., Yasui H., et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005, 106:1042-1047.
25. Dun X., Jiang H., Zou J., Shi J., Zhou L., Zhu R., et al. Differential expression of DKK-1 binding receptors on stromal cells and myeloma cells results in their distinct response to secreted DKK-1 in myeloma. Mol Cancer 2010, 9:247.
26. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8:751-764.
27. Glass D.A., Karsenty G. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann N Y Acad Sci 2006, 1068:117-130.
28. Guo J., Liu M., Yang D., Bouxsein M.L., Saito H., Galvin R.J., et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 2010, 11:161-171.
29. Wang F.S., Ko J.Y., Lin C.L., Wu H.L., Ke H.J., Tai P.J. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007, 40:485-492.
30. Spencer G.J., Utting J.C., Etheridge S.L., Arnett T.R., Genever P.G. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119:1283-1296.
31. Modarresi R., Xiang Z., Yin M., Laurence J. WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am J Pathol 2009, 174:123-135.
32. Qiang Y.W., Endo Y., Rubin J.S., Rudikoff S. Wnt signaling in B-cell neoplasia. Oncogene 2003, 22:1536-1545.
33. Edwards C.M., Edwards J.R., Lwin S.T., Esparza J., Oyajobi B.O., McCluskey B., et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008, 111:2833-2842.